SC
VIVO

Skylands Capital’s Meridian Bioscience Inc VIVO Stock Holding History

Skylands Capital’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-19,350
Closed -$342K – 254
2014
Q3 		$342K Sell
19,350
-54,050
-74% -$1.06M 0.03% 209
2014
Q2 		$1.51M Buy
+73,400
New +$1.51M 0.15% 131
2013
Q3 		– Sell
-14,800
Closed -$318K – 233
2013
Q2 		$318K Buy
+14,800
New +$319K 0.04% 188

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Skylands Capital's VIVO Position: Q4 2014 in Review

Skylands Capital sold out of Meridian Bioscience Inc (VIVO) in Q4 2014, closing a stake of 19,350 shares — an estimated $342K sold.

Skylands Capital first reported a position in VIVO in Q2 2013 and held it in 3 quarters. The position peaked at $1.51M in Q2 2014. 160 funds tracked by Wall St. Rank hold VIVO as of Q4 2014.

  • Skylands Capital reported no remaining Meridian Bioscience Inc position as of Q4 2014 after selling out during the quarter.
  • Skylands Capital sold 19,350 Meridian Bioscience Inc shares in Q4 2014, an estimated $342K.
  • Skylands Capital first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 3 quarters.
  • Skylands Capital's Meridian Bioscience Inc position peaked at $1.51M in Q2 2014.
  • 160 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2014.

Based on Skylands Capital's 13F filing for Q4 2014, filed 23 Jan 2015.